Investors & Media
Press Releases
<u>Press</u> Releases
July 31, 2024
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
May 8, 2024
Alcyone Therapeutics Announces Appointment of Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer and Head of Research & Development
January 3, 2024
Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
June 27, 2023
Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
January 4, 2023
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
May 18, 2022
Alcyone Presents Preclinical Data on Gene Therapy Programs with The Center for Gene Therapy at The Abigail Wexner Research Institute (AWRI) at ASGCT 2022
May 2, 2022
Alcyone Announces Two Oral Presentations on its Gene Therapy Platforms at The 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
October 25, 2021
Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments
June 9, 2021
Alcyone Therapeutics Launches to Advance Next-Generation Gene Therapies for CNS Disorders with $23 Million in Funding Contribution from RTW Investments
March 11, 2019
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx™ System